专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08440223B2 Sustained release pharmaceutical compositions comprising quetiapine in non-gellable polymers 有权
标题翻译：包含不可凝胶聚合物中的喹硫平的缓释药物组合物
公开(公告)号：US08440223B2
公开(公告)日：2013-05-14
申请号：US13002277
申请日：2009-06-29
申请人： Avinash Krishnaji Velhal , Sunil Anantrao Mirajkar , Virendra Ramkrupal Kuril , Vineeth Raghavan , Ninad Deshpanday
发明人： Avinash Krishnaji Velhal , Sunil Anantrao Mirajkar , Virendra Ramkrupal Kuril , Vineeth Raghavan , Ninad Deshpanday
IPC分类号： A61K9/14 , A61K9/20 , A61K9/48
CPC分类号： A61K9/2027 , A61K9/2054 , A61K9/2846 , A61K9/2866 , A61K31/554
摘要： A sustained release dosage form comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more non-gellable release controlling polymer and one or more pharmaceutically acceptable excipient(s). A sustained release dosage form comprising first granulation comprising Quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof and one or more release controlling material; and second granulation comprising one or more release controlling material which is the same or different than the one or more release controlling material of the first granulation and optionally quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof. A method of preparing the sustained release dosage form by first and second granulation followed by milling; blending the said milled granules after second granulation with lubricant followed by compression to form a sustained release dosage form. A sustained release dosage form comprising immediate release core comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more pharmaceutically acceptable excipients; and sustained release coating comprising one or more non-gellable release controlling material.
摘要翻译：包含喹硫平或其药学上可接受的盐，多晶型物，溶剂合物，水合物和一种或多种不可凝胶释放控制聚合物和一种或多种药学上可接受的赋形剂的持续释放剂型。一种持续释放剂型，其包含包含喹硫平或其药学上可接受的盐，多晶型物，溶剂合物，水合物和一种或多种释放控制材料的第一颗粒; 和第二制粒剂，其包含与第一制粒的一种或多种释放控制材料相同或不同的一种或多种释放控制材料，以及任选的喹硫平或其药学上可接受的盐，多晶型物，溶剂合物，水合物。通过第一次和第二次造粒然后研磨制备缓释剂型的方法; 在第二次造粒之后将所述研磨的颗粒与润滑剂混合，然后压缩以形成缓释剂型。包含立即释放核心的缓释剂型包含喹硫平或其药学上可接受的盐，多晶型物，溶剂合物，水合物和一种或多种药学上可接受的赋形剂; 以及包含一种或多种不可凝胶释放控制材料的持续释放涂层。

2. 发明申请

US20130323309A1 Sustained Release Composition of Memantine 审中-公开
标题翻译：美金刚的持续释放组成
公开(公告)号：US20130323309A1
公开(公告)日：2013-12-05
申请号：US14000264
申请日：2012-02-07
申请人： Pravin Meghrajji Bhutada , Ashish Ashokrao Deshmukh , Sajeev Chandran , Vineeth Raghavan , Shirishkumar Kulkarni
发明人： Pravin Meghrajji Bhutada , Ashish Ashokrao Deshmukh , Sajeev Chandran , Vineeth Raghavan , Shirishkumar Kulkarni
IPC分类号： A61K9/50 , A61K31/13
CPC分类号： A61K9/5073 , A61K9/1676 , A61K9/5047 , A61K9/5078 , A61K31/13
摘要： A sustained release pharmaceutical composition comprising; a core including memantine or its pharmaceutically acceptable salts and one or more pharmaceutical acceptable excipients, and a sustained release coating comprising a water insoluble substance and a water soluble substance where the ratio of the water insoluble substance to the water soluble substance is from about 1:0 to about 3:5:1, optionally containing an immediate release coating having memantine where the immediate release coating is applied over the sustained release coating.
摘要翻译：一种缓释药物组合物，其包含：包括美金刚或其药学上可接受的盐和一种或多种药学上可接受的赋形剂的核心，以及包含水不溶性物质和水溶性物质的持续释放包衣，其中水不溶性物质与水溶性物质的比例为约1： 0至约3：5：1，任选地包含具有美金刚的速释涂层，其中速释涂层施用于缓释涂层上。

3. 发明申请

US20110151002A1 SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING QUETIAPINE 有权
标题翻译：持续发布包含QUETIAPINE的药物组合物
公开(公告)号：US20110151002A1
公开(公告)日：2011-06-23
申请号：US13002277
申请日：2009-06-29
申请人： Avinash Krishnaji Velhal , Sunil Anantrao Mirajkar , Virendra Ramkrupal Kuril , Vineeth Raghavan , Ninad Deshpanday
发明人： Avinash Krishnaji Velhal , Sunil Anantrao Mirajkar , Virendra Ramkrupal Kuril , Vineeth Raghavan , Ninad Deshpanday
IPC分类号： A61K9/14 , A61K31/554 , A61K9/00 , A61P25/18
CPC分类号： A61K9/2027 , A61K9/2054 , A61K9/2846 , A61K9/2866 , A61K31/554
摘要： A sustained release dosage form comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more non-gellable release controlling polymer and one or more pharmaceutically acceptable excipient(s). A sustained release dosage form comprising first granulation comprising Quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof and one or more release controlling material; and second granulation comprising one or more release controlling material which is the same or different than the one or more release controlling material of the first granulation and optionally quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof. A method of preparing the sustained release dosage form by first and second granulation followed by milling; blending the said milled granules after second granulation with lubricant followed by compression to form a sustained release dosage form. A sustained release dosage form comprising immediate release core comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more pharmaceutically acceptable excipients; and sustained release coating comprising one or more non-gellable release controlling material.
摘要翻译：包含喹硫平或其药学上可接受的盐，多晶型物，溶剂合物，水合物和一种或多种不可凝胶释放控制聚合物和一种或多种药学上可接受的赋形剂的持续释放剂型。一种持续释放剂型，其包含包含喹硫平或其药学上可接受的盐，多晶型物，溶剂合物，水合物和一种或多种释放控制材料的第一颗粒; 和第二制粒剂，其包含与第一制粒的一种或多种释放控制材料相同或不同的一种或多种释放控制材料，以及任选的喹硫平或其药学上可接受的盐，多晶型物，溶剂合物，水合物。通过第一次和第二次造粒然后研磨制备缓释剂型的方法; 在第二次造粒之后将所述研磨的颗粒与润滑剂混合，然后压缩以形成缓释剂型。包含立即释放核心的缓释剂型包含喹硫平或其药学上可接受的盐，多晶型物，溶剂合物，水合物和一种或多种药学上可接受的赋形剂; 以及包含一种或多种不可凝胶释放控制材料的持续释放涂层。

4. 发明申请

US20100055181A1 CONTROLLED RELEASE DOSAGE FORMS OF ZOLPIDEM 审中-公开
标题翻译：控制释放剂量的ZOLPIDEM
公开(公告)号：US20100055181A1
公开(公告)日：2010-03-04
申请号：US12517487
申请日：2007-02-07
申请人： Nilesh Bhandari , Vineeth Raghavan , Surya Kumar Jayanthi , Himadri Sen
发明人： Nilesh Bhandari , Vineeth Raghavan , Surya Kumar Jayanthi , Himadri Sen
IPC分类号： A61K9/32 , A61K31/437 , A61K9/20 , A61K9/10 , A61K9/16
CPC分类号： A61K9/2054 , A61K9/0004 , A61K9/209 , A61K9/5047 , A61K9/5078
摘要： A controlled release dosage forms comprising zolpidem or a salt thereof to release zolpidem to induce rapid onset of sleep, and continue to release zolpidem in a controlled manner to maintain effective plasma concentrations over an extended period of time to improve sleep maintenance. The pharmaceutical controlled-release dosage form of zolpidem or a salt thereof having a dissolution profile when measured in a type I or II dissolution apparatus according to the U.S. Pharmacopoeia in 0.01M hydrochloric acid buffer at 37° C., such that less than 40% is released at the end of 30 minutes.
摘要翻译：包含唑吡旦或其盐的控制释放剂型，以释放唑吡旦以诱发快速睡眠发作，并以受控的方式继续释放唑吡旦，以在更长的时间内维持有效的血浆浓度以改善睡眠维持。当在0.01M盐酸缓冲液中在37℃下按照美国药典在I型或II型溶出装置中测量时，唑吡旦或其盐的药物控制释放剂型具有溶出曲线，使得小于40％在30分钟结束时发布。

5. 发明申请

US20070231385A1 Controlled Release Pharmaceutical Composition and a Process for Preparing the Same 审中-公开
标题翻译：控制释放药物组合物及其制备方法
公开(公告)号：US20070231385A1
公开(公告)日：2007-10-04
申请号：US10574320
申请日：2004-09-29
申请人： Himadri Sen , Suryakumar Jayanthi , Vineeth Raghavan , Ganga Arra
发明人： Himadri Sen , Suryakumar Jayanthi , Vineeth Raghavan , Ganga Arra
IPC分类号： A61K9/24 , A61K31/505 , A61K31/535 , A61K31/551 , A61K47/38
CPC分类号： A61K9/209
摘要： A three-drug antiretrovial pharmaceutical composition having a selective combination of a controlled release active formulation and an immediate release active formulation for once daily administration. The composition provides desired dosages of the actives lamivudine, zidovudine or pharmaceutically acceptable derivatives thereof, and the immediate release formulation including at least one selective Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI), preferably nevirapine or a pharmaceutically acceptable derivative thereof along with pharmaceutically acceptable excipients. The once daily composition would favour patient compliance and effective treatment. A method of reducing the pill burden in a patient suffering from HIV infection and/or Acquired Immunodeffieciency Syndrome by administering a once daily dose of the three-drug antiretroviral pharmaceutical composition.
摘要翻译：一种三药抗逆转录药物组合物，其具有控释活性制剂和立即释放活性制剂的选择性组合，每日一次给药。所述组合物提供所需剂量的拉米夫定，齐多夫定或其药学上可接受的衍生物，并且立即释放制剂包括至少一种选择性非核苷逆转录酶抑制剂（NNRTI），优选奈韦拉平或其药学上可接受的衍生物以及药学上可接受的赋形剂。每天一次的组合将有利于患者的顺应性和有效的治疗。一种通过施用一日剂量的三药抗逆转录病毒药物组合物来减少患有HIV感染和/或获得性免疫缺陷综合征的患者的药丸负担的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式